newsfilter
← Latest News
Business Wire·

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

- Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment - - Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension